子宮頸浸潤性癌組織中α-SMA和FAP表達及臨床意義
[Abstract]:Objective to investigate the expression of 偽 -smooth muscle actin (偽 -SMA) and fibroblast-activating protein in normal cervix, cervical intraepithelial neoplasia (cervical intraepithelial neoplasias cin) and invasive cervical carcinoma. The relationship between the expression and clinicopathological parameters, invasion and metastasis and prognosis of invasive cervical carcinoma was analyzed. Methods the expression of 偽 -SMA and FAP in 20 cases of normal cervical carcinoma and 98 cases of invasive carcinoma of cervix were detected by immunohistochemical Eli Vision two-step method. To compare the expression of 偽 -SMA and FAP in the three groups and their correlation with the clinicopathological features of invasive cervical carcinoma. Results 偽 -SMA and FAP were not expressed in cin of normal cervical carcinoma. Both of them were expressed in the cytoplasm of the interstitial fibroblasts of cervical carcinoma. The positive rate of 偽 -SMA was 82.7% (81 / 98), and the positive rate of 偽 -SMA was 82.7% (81 / 98), and the positive rate of 偽 -SMA was 82.7% (81 / 98) in the stroma of cervical invasive carcinoma, and the positive rate of 偽 -SMA was 82.7% (81 / 98), which was correlated with the clinical stage. Pathological grade and lymph node metastasis correlated (P0.05) the positive rate of FAP was 79.6% (78 / 98) in the interstitial of invasive carcinoma of the cervix and correlated with clinical stage, pathological grade and lymph node metastasis (P0.05), 偽 -SMA and FAP were correlated with the age of the patients. There was no significant difference in tumor size (P0.05). 偽 -SMA and FAP expression were consistent in the region and positively correlated with the expression intensity in invasive cervical carcinoma. The linear correlation between 偽 -SMA and FAP was linear (r = 0.829, P = 0.000). Conclusion 偽 -SMA and FAP may play a certain role in the growth, invasion and metastasis of invasive cervical carcinoma, and can be used as a reliable index to predict the prognosis of invasive cervical carcinoma.
【作者單位】: 吉林省通化市人民醫(yī)院病理科;北華大學(xué)基礎(chǔ)醫(yī)學(xué)院病理教研室;
【分類號】:R737.33
【相似文獻】
相關(guān)期刊論文 前10條
1 王愛梅;;大面積左乳浸潤性癌伴全身多發(fā)轉(zhuǎn)移患者放化療的護理[J];中國實用醫(yī)藥;2013年13期
2 詹天棋,陳梓甫,陳文榜,詹漢雄,王怡,林振石;全膀胱浸潤性癌(附四例報告)[J];中華泌尿外科雜志;1997年08期
3 陳麗嬌;陳少明;張慧珍;;大面積左乳浸潤性癌伴全身多發(fā)轉(zhuǎn)移患者放化療的護理[J];中國當(dāng)代醫(yī)藥;2012年04期
4 湯華豐;陳志讓;馬小葵;;骶尾部浸潤性癌肉瘤一例報告[J];上海醫(yī)學(xué);1986年03期
5 袁孝賓;局部粘連激酶基因表達與浸潤性癌[J];國外醫(yī)學(xué)(腫瘤學(xué)分冊);1994年03期
6 王紅衛(wèi);張雯靜;;10例伴發(fā)相應(yīng)部位浸潤性癌的乳腺外派杰氏病分析[J];重慶醫(yī)學(xué);2006年23期
7 王德延;;乳腺導(dǎo)管癌中管內(nèi)癌和浸潤性癌所占的比例對預(yù)后的意義[J];國外醫(yī)學(xué)參考資料(腫瘤學(xué)分冊);1974年03期
8 陳林;;超聲診斷乳腺導(dǎo)管浸潤性癌分析[J];現(xiàn)代診斷與治療;2013年01期
9 谷彥軍,馬鴻達,古強,王健;乳腺導(dǎo)管內(nèi)增生性病變及浸潤性癌中樹突狀細(xì)胞的檢測[J];臨床與實驗病理學(xué)雜志;2005年01期
10 龐磊;邵晉凱;姜煥榮;;膀胱尿路上皮浸潤性癌合并結(jié)核性肉芽腫1例伴文獻復(fù)習(xí)[J];求醫(yī)問藥(下半月);2011年12期
相關(guān)重要報紙文章 前1條
1 北京腫瘤醫(yī)院 劉晨邋王倫;如何讀懂乳腺癌病理報告[N];中國醫(yī)藥報;2007年
,本文編號:2175599
本文鏈接:http://sikaile.net/yixuelunwen/fuchankeerkelunwen/2175599.html